Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.

ABSTRACT:

Introduction

Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer treatment. De novo and acquired resistance, however, is common. The aims of this study were to relate patterns of copy number aberrations to molecular and proliferative response to AIs, to study differences in the patterns of copy number aberrations between breast cancer samples pre- and post-AI neoadjuvant therapy, and to identify putative biomarkers for resistance to neoadjuvant AI therapy using an integrative analysis approach.

Methods

Samples from 84 patients derived from two neoadjuvant AI therapy trials were subjected to copy number profiling by microarray-based comparative genomic hybridisation (aCGH, n=84), gene expression profiling (n=47), matched pre- and

SUBMITTER: Lopez-Knowles E 

PROVIDER: S-EPMC4406016 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature